Among healthcare ETFs, VHT stands out in my view as the most representative of the sector, in terms of performance, risk, and ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

The head of drugmaker Eli Lilly, which sells the popular weight-loss drug Zepbound, urged the Trump administration to ease up on its tariff rollout because it could hurt Lilly’s business and the ...

The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

"The Novo Nordisk Foundation is increasing its influence and has appointed its chairman, Lars Rebien Sørensen, as an observer ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Amid concerns over trade restrictions and a weakening economy, some investors are seeking stability in dividend-paying stocks ...

Looking at its longer-term performance, Eli Lilly's stock appreciated by 422.93% over the past five years, reflecting ...

Elanco Animal Health saw its share prices soar by 26.29 percent on Wednesday to end at $12.01 apiece following an impressive ...

Eli Lilly has been building its presence in ALS and other neurodegenerative diseases. Credit: Scott Olson via Getty Images. UK-based Alchemab has secured a licensing agreement worth up to $415m with ...

Eli Lilly’s (NYSE:LLY) stock faced a notable decline following the company’s announcement ... Analysts maintain a ‘Buy’ recommendation, with a target mean price of $991.9726, suggesting optimism about ...